These days, there is no shortage of companies fighting Alzheimer’s disease. Some are having much better luck at it than others, though, with NeuroSense Therapeutics (NASDAQ:NRSN) being one such company. The news that nearly doubled the share prices of NeuroSense came from the results of a biomarker study. Specifically, NeuroSense found that levels of a biomarker known as TDP-43 were higher in Alzheimer’s patients than it was in a control group of healthy people.
NeuroSense then stepped up the study by adding a larger control group, which would help underscore the results. TDP-43 has been seen previously in both “senile plaques” and “neurofibrillary tangles.” This suggests that TDP-43 might have a direct connection to amyloid-beta or tau.
NeuroSense’s combination therapy, meanwhile, has already delivered on the notion of reducing TDP-43 in patients. The new results are sufficient enough that the company can now move to a phase 2 proof-of-concept test starting in the first half of this year. It’s still a long way before NeuroSense can claim it has an effective treatment for Alzheimer’s. However, if it gets to that point, it will likely become a much more valuable company in short order.
The last five trading days for NeuroSense have been about what you’d expect for a company that had a breakthrough moment. It spent the last five days comparatively flat until an explosive upshot. It’s retraced a bit from its absolute highs but is still close to double what it was yesterday.
Join our Webinar to learn how TipRanks promotes Wall Street transparency
